Skip to main content
. 2023 Jan 31;41(10):1830–1840. doi: 10.1200/JCO.22.02186

FIG 1.

FIG 1.

DFS per investigator assessment. Kaplan-Meier estimates of duration of (A) DFS in patients with stage II-IIIA disease and (B) in the overall population (stage IB-IIIA) by seventh edition staging per the protocol (full analysis set). Tick marks indicate censored data. An HR < 1 favors osimertinib. DFS, disease-free survival; HR, hazard ratio; NC, not calculated.